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Abstract
Deleted in Liver Cancer (DLC) proteins
belong to the family of RhoGAPs and are
believed to operate as negative regulators of
the Rho family of small GTPases. So far,
the role of the first identified member from
the DLC family, DLC1, was established as
a tumor suppressor in hepatocellular carci-
noma. The function of its close family rela-
tive, DLC2 is unequivocal. In the present
study we attempted to determine whether
the loss of DLC2 is a common feature of
hepatocellular carcinoma tissue. We exam-
ined two types of hepatocellular carcinoma-
typical and fibrolamellar one. Our analysis
revealed that DLC2 protein is not dimin-
ished in cancer tissue when compared to
non-cancerous liver specimens. What is
more, we observed DLC2 to be more abun-
dantly expressed in cancer tissue, particu-
larly in tumors with the inflammation back-
ground. In addition, we found that DLC2
gene status was diploid in virtually all
tumor samples examined. Our results indi-
cate that DLC2 is not diminished in hepato-
cellular carcinoma cells. It appears that
members of the DLC family, although
structurally highly related, may function
differently in cancer cells.
Introduction
Hepatocellular carcinoma (HCC)
remains a serious oncological issue and rep-
resents the fourth leading cause of cancer-
related deaths worldwide.1,2 This is the most
common primary liver cancer which devel-
ops predominantly in patients with underly-
ing cirrhotic liver disease of various etiolo-
gies.3 Although great progress has been
made in understanding the biology of can-
cer in recent decades, the pathophysiology
of HCC is still poorly characterized. As
many studies highlight HCC is a complex
disease and there is no dominant molecular
pathway which underlies its development
and progression.4 To date, tumor resection
seems the most effective method of treat-
ment; alternatively, in some cases of liver
transplantation, chemoembolization and
thermoablation may be also beneficial for
patients.5 Within the group of hepatocellular
carcinomas, the fibrolamellar variant (FL)
is particularly interesting as its etiology is
completely different. It usually affects
young adults and most patients do not have
liver cirrhosis or other co-existing liver dis-
ease.6 To date there are not many literature
data available describing the risk factors
and molecular changes associated with the
development of FL.7-9
Findings of numerous studies showed
that Rho signaling pathways are altered in
human cancers.10 One of the major causes
of these alterations is the disruption of
genes encoding proteins that regulate Rho
proteins function, namely Rho GTPase acti-
vating proteins (RhoGAPs). DLC2 is a
member of broader Deleted in Liver Cancer
protein family, which belongs to the
RhoGAP super family.11 Typical DLC pro-
tein contains three functional domains - the
Sterile Alpha Motif (SAM), the Rho GAP
and Steroidogenic Acute Regulatory
Related Lipid Transfer (START) domain.12
The tumor suppressor function is linked
mainly to its RhoGAP activity, however
other parts of the protein, i.e., SAM domain
may regulate this activity as well.13-15
The best characterized member of DLC
family, DLC1, is frequently deleted in dif-
ferent types of cancer and its tumor sup-
pressive function has been clearly evi-
denced.16,17 The following identified gene
from the DLC family, DLC2, has been stud-
ied to a lesser extent. This gene is located on
chromosome 13q12, a region exposed to the
allelic loss, as was documented in several
human cancers.18 The DLC2 protein is 50%
identical to DLC1, shares the same func-
tional domains and functions through a sim-
ilar mode of action. DLC2 expression was
found to be down-regulated in several types
of cancer, including lung, renal, ovarian,
breast, colon and rectal tumors.19 To date,
there are limited literature reports which
address the DLC2 function, nevertheless, it
has been shown that it can regulate the
growth of tumor cells by modulating RhoA
activity and thus inhibits cell motility.20 In
addition, DLC2 was found to affect Ras sig-
naling and inhibit Ras-mediated cell trans-
formation.21
In this study we determined the pres-
ence and tissue/cellular localization of
DLC2 protein in HCC tumor samples. To
date, no studies have been carried out
addressing the expression of DLC2 in the
fibrolamellar subtype of HCC. Additionally,
we designed the genetic probe for DLC2 in
order to find (by the in situ hybridization
approach) whether the loss of this gene is a
common feature in both typical and fibro-
lamellar variant of HCC.
Materials and Methods
Tissue specimens
Tumor samples were obtained from 81
patients with diagnosed HCC, among this
group there were 9 tumors of the fibro-
lamellar subtype. Control group consisted
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of 25 normal liver tissue specimens.
Additionally, 10 tissue samples with
macroregenerative nodules were examined.
Ethics statement
The study was approved by the Medical
University of Warsaw Ethics Committee
(KBO/42/11).
Immunohistochemistry/ immunofluo-
rescence
The immunohistochemical staining, in
brief, was as follows. Formalin-fixed, paraf-
fin-embedded 4 mm sections were deparaf-
finized and rehydrated. To unmask antigen
sites sections were treated with high tem-
perature boiling in the 0.01 mol/L citrate
buffer pH 6.0 (DakoCytomation, Glostrup,
Denmark) for 2x7 min in the microwave
oven. Subsequently sections were incubated
with 3% hydrogen peroxide to block
endogenous peroxidase for 30 min and then
treated with 5% normal donkey serum
(Jackson Immunoresearch, West Grope, PA,
USA) for 30 min followed by Serum Free
Protein Block (DakoCytomation) 10 min
incubation to prevent unspecific binding of
antibodies. Then the goat anti-DLC2 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA)
antibody in 1:50 dilution was applied and
incubated overnight in moist chamber in
4°C. Detection of the primary antibody was
performed with the donkey anti-goat perox-
idase-conjugated (Jackson Immuno-
research) antibody in 1:500 dilution for 1 h.
To visualize the immunostaining 3, 3’-
diaminobenzidine (Dako) was used as a
chromogen.
Immunohistochemical results of DLC2
staining were quantified by the morphome-
tric analysis using a Nikon Eclipse 80i
microscope and Image Pro Plus software.
From each patient, 10 random fields were
photographed at 20x magnification. On
every image the area covered by the
immunoreactivity, as well as the mean
intensity of staining, were quantified.
Within a given field, the product of
immunoreaction intensity times the area
was considered as an approximation of the
total immunoreactivity, and displayed in
arbitrary units. For immunofluorescence
studies primary antibodies were detected
with donkey anti- goat Alexa555 in dilution
1:200 (for DLC2) and donkey anti- rabbit
Alexa488 in dilution 1:200 (for mitochon-
dria) secondary antibodies conjugated with
fluorophores (both from Invitrogen,
Carlsbad, CA, USA). For colocalisation
studies rabbit anti-hepatocytes antibody
(Biogenex, Fremont, CA, USA) was
applied. After immunostaining sections
were mounted with the Vectashield mount-
ing medium containing DAPI (Vector
Laboratories, Burlingame, CA, USA).
Immunofluorescence was analyzed under a
high-resolution Leica TCSSP5 Confocal
microscope (Leica Microsystems, Wetzlar,
Germany).
Fluorescence in situ hybridization
Probe preparation
The DLC2 sequence was obtained from
BAC DNA library (CHORI, Children’s
Hospital Oakland Research Institute,
Oakland, CA, USA) as bacterial LB agar
stab culture. E. coli were cultured in LB
agar with chloramphenicol, passaged as a
single isolated colony and subjected to a
rapid alkaline DNA isolation by EndoFree
Plasmid Maxi Kit (Qiagen, Hilden,
Germany). Extracted DNA was amplified
by GenomiPhi DNA Amplification Kit (GE
Healthcare, Chicago, IL, USA).
Subsequently dUTP were labeled with
digoxygenin or biotin Translation Mix
(Roche Applied Science, USA) and probe
was labeled by the nick-translation method
according to Cremer et al.22
Hybridization procedure - modified
method of Cremer et al.
For hybridization procedure sections
were deparaffinized and hydrated in a series
of alcohol. Subsequently digestion with
pepsin and tissue permeabilization with
sodium thiocyanate at 80°C were per-
formed. Then sections were equilibrated in
50% formamide/2xSSC, prehybridized in
45°C, denatured in 80°C and hybridized for
40 h. In brief, post-hybridization procedures
were done by incubation sections in 2xSSC
and 0.1xSSC in 60°C 2x10 min. Detection
of biotin-conjugated probes was performed
by the incubation with avidin-Alexa488
(Molecular Probes, Eugene, OR, USA) and
anti-avidin-FITC (Sigma Aldrich, St. Louis,
MO, USA) antibodies. Detection of digoxy-
genin-conjugated probes was performed
with the anti-digoxigenin – rhodamine
sheep antibody (Roche Applied Science,
Penzberg, Germany). In order to visualize
the nuclei, sections were stained with
Hoechst reagent (Molecular Probes).
Specimens were examined under Nikon
Eclipse 80i fluorescent microscope (Nikon,
Tokyo, Japan). To assess the gene status in
each section, 200 cells were counted at
600x magnification.
Statistical analysis
Differences between groups were ana-
lyzed by the non-parametric Mann-Whitney
U test. Statistical correlations were evaluat-
ed by the Spearman’s rank correlation coef-
ficient test.
Results
DLC2 immunoreactivity is more
prominent in hepatocellular carcino-
ma when compared to the normal
liver
In the normal liver DLC2 immunoreac-
tivity was present in virtually all hepato-
cytes in a form of diffused, cytoplasmic
staining (Figure 1a). Similar pattern of
staining was observed in sections with
macroregenerative nodules (Figure 1b). We
found cancer cells to be more intensively
stained when compared to normal hepato-
cytes (Figure 1 c,d). What is more, in HCC
cells, apart from cytoplasmic, nuclear
DLC2 immunoreactivity was observed as
well (Figure 1e). Statistical analysis of mor-
phometric measures revealed significantly
more DLC2 expression in HCC when com-
pared to either normal liver or macroregen-
erative nodules (Mann-Whitney U test, P=
0.0004 and P= 0.0034 respectively, Figure 1
h). We found that DLC2 was more promi-
nently expressed in these tumors that devel-
oped in the liver with the inflammation
(P=0.049; Mann-Whitney U test; Figure 1
f,i). In FL sections the DLC2 staining pat-
tern was similar to that observed in a typical
HCC (Figure 1e). A negative control, per-
formed with the use of rabbit immunoglob-
ulins applied with the same concentration as
the primary antibody, displayed no
immunoreactivity (Figure 1g). To check
whether DLC2 localizes to mitochondria
we performed double immunofluorescence
staining with anti-DLC2 and anti-mitochon-
dria antibodies which was analyzed under
the high-resolution confocal microscopy.
We found that both DLC2 and mitochondria
were more prominently expressed in tumor
cells when compared to the adjacent liver
(Figure 1 j,k). However, we did not find
profound overlap between these two
immunoreactivities (Figure 1 l,m).
The copy number of the DLC2 gene
is diploid in HCC specimens
Fluorescent in situ studies with probes
designed for the DLC2 gene showed that in
the majority of tumor samples that were
tested, the number of DLC2 copies was
diploid in cancer cells (Figure 2 a,b). The
loss of one copy of the DLC2 gene was
detected in 3 out of 18 examined tumors. In
two of these cases the loss correlated with a
slightly decreased DLC2 expression, but in
one of them had no effect on the level of
protein. The gene deletion was found to be
independent of the HCC subtype.
                                                                                                        Original Paper
[European Journal of Histochemistry 2019; 63:2981] [page 33]
N
n-c
om
me
rci
al 
us
e o
nly
[page 34]                                             [European Journal of Histochemistry 2019; 63:2981]
                             Original Paper
Figure 1. DLC2 immunoreactivity in the normal liver and hepatocellular carcinoma. a) Staining in the normal liver. b) Staining in
macroregenerative nodules. c) DLC2 immunoreactivity on the border zone (marked with white arrows) between the normal liver and
HCC. d) HCC with heterogeneous staining. e) Staining in FL, note the nuclear staining marked with yellow arrows. f ) Strong staining
in HCC with the inflammation. g) Control immunoreaction. h) A graph showing the difference in DLC2 immunoreactivity between
normal liver, HCC and macroregenerative nodules, [au] arbitrary units. i) A graph showing the difference in DLC2 immunoreactivity
between HCC with (IF) and without (no IF) inflammation. j) Combined immunofluorescence of DLC2 (red), mitochondria (green)
and cell nuclei (blue); upper part of the image depicts the remaining liver, whereas lower part tumor masses (the border zone is pointed
by white stars), note stronger both DLC2 and mitochondria immunoreactivities within cancer cells. k) The same immunofluorescence
image as in J with the extracted DLC2 immunofluorescence (red). l, m) High power images with immunofluorescence of DLC2 (red)
and mitochondria (green) in hepatocyte and in cancer cell, note that DLC2 immunoreactivity forms large granules in hepatocyte,
whereas in cancer cell DLC2 immunoreactivity is scattered along cellular cytoplasm. Scale bars: a,c,d,f,g) 50 µm; e) 20 µm; b,j,k) 100
µm; l, m) 5 µm.
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Discussion
In the current study we document the
presence of both protein and gene DLC2 in
two types of hepatocellular carcinoma –
classical and fibrolamellar one. We demon-
strate novel results which indicate that
DLC2 unlike its relative, DLC1, does not
undergo genetic deletion in cancer cells.
Moreover, we display that the DLC2 pro-
tein is more abundantly expressed in cancer
cells when compared to normal hepato-
cytes, especially when the cancer develops
with the considerable inflammation back-
ground. We show also that the tissues with
macroregenerative nodules have a similar
level of DLC2 immunoreactivity to the
level observed in normal liver sections. For
both the gene and the DLC2 protein status
we did not observe any differences between
the two types of hepatocellular carcinoma –
classical and fibrolamellar variant. It was
found that the expression and function of
the DLC2 gene in cancer is ambiguous.
Early reports have shown that DLC2 pos-
sesses growth suppressive function and its
expression is reduced in about 18% of hepa-
tocellular carcinoma tissues.21 Subsequent
studies revealed tumor suppressive function
of DLC2 through RhoA downregulation
followed by inhibition of cell proliferation
and migration in vitro.20 In a cancer profil-
ing study, which included other types of
solid tumors, i.e. lung, breast and rectal,
Ullmannova et al. showed that both DLC1
and DLC2 are underexpressed, however to
a different degree.19 On contrast to the stud-
ies mentioned above, Yau et al. demonstrat-
ed, using the knockout mouse models, that
DLC2 deficiency did not predispose to
HCC formation, even in the presence of
chemical hepatocarcinogen.23 Interesting
results were also presented in a work of
Basak et al., where authors showed that in
the mammary cancer model the DLC2 dele-
tion did not change the tumor growth, how-
ever it had an impact on the metastasis for-
mation, which suggests its metastasis sup-
pressor rather than tumor suppressor role.24
Our results did not confirm the DLC2 defi-
ciency as a common feature of HCC at the
protein and gene levels in our experimental
group. Similar results were presented in the
work of Wang et al., where authors showed
that the major member of the DLC family
whose expression is reduced in HCC is
DLC1, while the expression of DLC2 was
not diminished and even was increased in
the subset of tumors.25 In our experimental
group we noted increased DLC2 immunore-
activity in a small part of HCC samples.
Such increased immunoreactivity was asso-
ciated with the abundant presence of
inflammatory cells. It appears that the
inflammation process may affect the
expression of DLC2, but the mechanism of
this relationship remains to be determined.
Interestingly, we found DLC2
immunoreactivity in macroregenerative
nodules to be similar to the one seen in the
control group. These structures represent
the state in the liver where active tissue
remodeling occurs as a result of different
liver injury. It looks that the abundant pres-
ence of DLC2 is not common for such
benign lesions, and some additional factors
in cancer cells trigger its excessive expres-
sion. Such result indicates that DLC2
immunoreactivity can potentially differenti-
ate the non-malignant nodules vs HCC.
However, such use of DLC2 immunostain-
ing for diagnostic purposes requires further
research.
The loss of one copy of the gene was
established as the principal mechanism of
DLC1 underexpression in HCC, while the
status of the DLC2 gene was studied less
extensively. In our study we detected a loss
of gene copy in a small percentage of the
tumor samples tested. Available literature
data indicated that loss of DLC2 copy num-
ber occurs only in a subset of HCC speci-
mens which implicates that such a mecha-
nism of the protein underrepresentation is
not a common attribute in this type of can-
cer.25
We observed DLC2 protein localized
mainly in the cytoplasm of cancer cells. As
was demonstrated on hepatoma cells, DLC2
was found to be located in mitochondria
through the START domain.26 To investi-
gate this issue on HCC sections, we per-
formed double immunofluorescence studies
with anti-DLC2 and anti-mitochondrial
antigens. However, we did not find a signif-
icant colocalization of both proteins, in both
normal hepatocytes and cancer cells, indi-
cating that this interaction does not appear
to be a common feature of hepatocellular
carcinoma cells. Interestingly, we found a
cancer cell population with DLC2 located
in nuclei, which was not observed in normal
hepatocytes. So far there were no studies
showing DLC2 localized in cancer cell
nuclei, but the presence of the SAM domain
within the protein structure, responsible i.e.
for the protein - DNA/RNA interaction sug-
gests possible DLC2 interactions with chro-
matin structures and thus possible impact
on various nuclear processes.27
DLC2 belongs to the broader family of
DLC proteins with high structure homology.
All DLC proteins contain three functional
domains: SAM, RhoGAP and START
domain.12 Since DLC2 structure is 50% iden-
tical to DLC1 their function may be overlap-
ping. Therefore, DLC2 presence in cancer
cells should be taken into consideration
whenever other members of this family,
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Figure 2. Fluorescence in situ hybridization with DLC2 probe in the normal liver and hepatocellular carcinoma. a) FISH result with
DLC2 probe in the normal liver. b) FISH result with DLC2 probe in HCC specimen. Probe signals were marked with round circles
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especially DLC1 are considered for possible
use in prevention, diagnosis, and therapies. 
To summarize, we demonstrated that
DLC2 protein expression is present in HCC
sections. Our findings question the DLC2
tumor suppressor activity by the mechanism
of gene and protein depletion in this type of
cancer. Increased DLC2 expression associ-
ated with the inflammation suggests its pos-
sible association with the inflammatory
process. A more detailed analysis of the
mechanisms regulating the activity of
DLC2 in the normal development and
pathogenesis of cancer is required to
explain its participation in the onset of
HCC. 
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